Seeking Alpha

Exidavnemab phase 2a study expanded to include MSA patients

STOCKHOLM, May 8, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in Poland have approved the inclusion of Multiple System ...
Nasdaq

Alterity (ATHE) Up on Interim Data From Advance MSA Study

Shares of Alterity Therapeutics ATHE were up 7.8% on Jul 17 after the company announced positive interim data from the phase II ATH434-202 study evaluating its lead pipeline candidate ATH434 for ...

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

Company is advancing ATH434 in late-stage clinical development for Multiple System Atrophy, a rapidly progressive neurodegenerative disease ...
sharewise

TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study

Shares of Theravance Biopharma TBPH plunged 26% after the company announced the failure of the late-stage CYPRESS study ...
Medscape

Autonomic Testing May Help Differentiate Multiple System Atrophy From Parkinson Disease

Multiple system atrophy (MSA) is often difficult to distinguish from Parkinson's disease (PD) with autonomic failure, but this is an important distinction for research studies as well as for clinical ...